Form 4: Alnylam EVP Tolga Tanguler Reports Stock Transactions Following PSU Vesting

Alnylam's EVP, Chief Commercial Officer Tolga Tanguler, reports acquisition of shares from performance-based stock units (PSU) and subsequent sales to cover tax obligations.

Summary

• On June 24, 2024, Tolga Tanguler, EVP, Chief Commercial Officer of Alnylam Pharmaceuticals, acquired 3,278 shares of common stock due to the vesting of a performance-based stock unit (PSU).
• The PSU vested because Alnylam publicly reported a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 clinical study in ATTR amyloidosis with cardiomyopathy.
• Following the vesting, Tanguler sold a total of 1,446 shares between June 25, 2024, at prices ranging from $221.71 to $235.73 per share to cover minimum statutory tax withholding obligations.
• After these transactions, Tanguler directly owns 11,660 shares of Alnylam common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of PSUs indicates the achievement of a clinical milestone, which is a positive sign for the company. The subsequent sale of shares is a routine transaction to cover tax obligations and does not necessarily reflect a negative outlook.

Positives

• The vesting of the PSU indicates the achievement of a significant performance milestone related to a Phase 3 clinical study.
• The positive clinical trial results likely contributed to the stock price at which the shares were sold.

Industry Context

This filing reflects routine transactions by a company executive following the achievement of a clinical milestone. Such transactions are common in the pharmaceutical industry, where stock-based compensation is a significant part of executive pay.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies, particularly in the pharmaceutical industry.
• Companies like Amgen, Biogen, and Vertex Pharmaceuticals also frequently report similar Form 4 filings related to stock options, restricted stock units, and performance-based awards.
• The vesting of PSUs based on clinical trial outcomes is a standard practice to align executive compensation with company performance and drug development milestones.

Stakeholder Impact

• The positive clinical trial results that triggered the PSU vesting could positively impact shareholders.
• The sale of shares by the executive may have a minimal impact on the stock price due to the relatively small volume of shares sold.

Key Dates